Clinical Trial Opportunities

Throughout the year, there may be one or more clinical trials available worldwide for Acromegalics to participate in. By joining and participating in clinical trials, you are helping other patients not only with early diagnosis at times, awareness, and improving quality of life.

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly

 Summary:
Currently two global trials are recruiting patients diagnosed with acromegaly in the United States. These trials evaluate the efficacy, safety and tolerability of CAM2029, a new long-acting investigational formulation of octreotide. For more information on the trials, please follow the link to the Acromegaly&ME site.
 
Clinical trial HS-18-633: A Phase 3, Randomized, Double-blind, Placebo controlled, Multi-center Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients With Acromegaly.
 
This trial (ClinicalTrials.gov Identifier: NCT04076462) is recruiting patients diagnosed with acromegaly who have been receiving regular treatment with octreotide or lanreotide. Patients that have been on a stable dose (of octreotide or lanreotide) for at least 3 months and have well-controlled levels of insulin-like growth factor 1 (IGF-1) may be eligible to participate.
 
Clinical trial HS-19-647: A Phase 3, Open-label, Single-arm, Multi-center Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients With Acromegaly.
 
This trial (ClinicalTrials.gov Identifier: NCT04125836) is recruiting patients diagnosed with acromegaly who have been receiving regular treatment with octreotide or lanreotide for at least 3 months. Patients can also have previously received radiotherapy (irradiation) treatment. Levels of insulin-like growth factor 1 (IGF-1) do not need to be well-controlled.  Patients who previously participated in and completed the HS-18-633 trial will be invited to continue participation for 6 months in the HS-19-647 trial.
 
Camurus AB is a Swedish biopharmaceutical company committed to developing long-acting medicines for the treatment of severe and chronic conditions.
 
Interested patients email: This email address is being protected from spambots. You need JavaScript enabled to view it.
 

Bone MicroArchitecture Clinical Trial Seeking Volunteers

Estimted Completion Date: March 2020
  
The following study, conducted by Dr. Pamela Freda of Columbia University, is now available for those located in the Northeastern USA and currently using Somavert.  This would be a great way to get your foot into the door of working with a great doctor and to advance research.
 
Dr. Freda is conducting a study entitled Pilot Study of Bone Microarchitecture in Pegvisomant Treated Patients. This study is open to patients treated with Pegvsiomant for at least 1 year with a normal IGF-1 level. It includes DXA, high resolution peripheral CT to examine bone micro architecture and measurement of bone markers and GH and IGF-1.
 
Requires a one-time 2-hour visit. The study is also registered on www.clinicaltrials.gov. 13 spots available at time of posting.
 
Interested patients call 212-305-4921 or 212-305-2254.

Ongoing Crinetics Studies in Acromegaly

CRN00808-02

A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF CRN00808 IN PATIENTS WITH ACROMEGALY THAT ARE RESPONDERS TO OCTREOTIDE LAR OR LANREOTIDE DEPOT

crinetics study evolve 300x101This Phase 2 study is now recruiting adult patients with acromegaly at participating sites in the United States and Europe. Patients who are treated with Octreotide LAR or Lanreotide Depot as their sole acromegaly medication and have normal IGF-1 levels may be eligible to participate. This study is active and currently recruiting new patients. For more information on this study, please follow the ClinicalTrials.gov link: NCT03792555.
Actual Study Start Date : October 10, 2019
Estimated Primary Completion Date : March 2022
Estimated Study Completion Date : April 2022
  
Brief Summary:
The purpose of this trial is to assess the efficacy and safety of CAM2029 in patients with acromegaly. Patients will be randomized to either CAM2029 or placebo administered subcutaneously once monthly during 6 months.
CRN00808-03

AN OPEN LABEL EXPLORATORY STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF CRN00808 IN PATIENTS WITH ACROMEGALY TREATED WITH SOMATOSTATIN ANALOGUE BASED TREATMENT REGIMENS

crinetics study edge 300x101This phase 2 study is now recruiting adult patients at participating sites in the United States and Europe. Patients who are currently treated with somatostatin-based treatments (e.g. Octreotide, Lanreotide, Pasireotide) may be eligible to participate. This study is active and currently recruiting new patients. For more information on this study, please follow the ClinicalTrials.gov link: NCT03789656..
Crinetics is focused on the discovery and development of novel therapeutics for rare endocrine diseases and endocrine-related tumors. As part of this mission, we conduct clinical trials to evaluate the safety and efficacy of investigational medicines. If you or someone you know is looking for information about the studies currently underway at Crinetics, you can view the information below, or for questions, contact us at This email address is being protected from spambots. You need JavaScript enabled to view it..

Other Active Clinical Trials

Global Clinical Trials

United Kingdom Trials

Spain Trials

Search Acromegaly-Related Clinical Trials

Acromegaly does not define us. We do not let our diagnosis hold us back from living a full and enriched life. Some have found passion, purpose, and inspiration through their diagnosis. These people bring inspiration, and we call this our "Faces of Hope".

Say hello.